SGS expands quantitative bioanalytical services for protein therapy development at Poitiers, France laboratory

The two new systems offer faster method development and the ability to quantify multiple proteins simultaneously.

The two systems, which are now installed and validated, are a combination of the AB SCIEX 6500+ and Shimadzu X2 UPLC, which offers high specificity, a wide dynamic range, faster method development and the ability to quantify multiple proteins simultaneously. LC-MS/MS techniques have a number of advantages over standard conventions for protein and peptide quantitation, which are based on ligand-binding assays (LBAs) such as the enzyme-linked immunosorbent assay (ELISA). Assay development can often be time-consuming and expensive and, in addition, LBA results are often plagued by interferences and high background from antibody cross-reactivity.

“Mass spectrometry platforms have universal applicability, providing one technique for a large diversity of analytes,” commented Dr Walid Elbast, Director LC-MS at SGS Poitiers. “All types of proteins and peptides can be quantified by LC/MS/MS without exception, and a wide diversity of other biomolecules such as lipids and carbohydrates can also be quantified, providing researchers with a highly sensitive, selective and flexible bioanalytical platform